Loading clinical trials...
Loading clinical trials...
An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit
Conditions
Interventions
BI 894999
Locations
16
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Brussels - HOSP Jules Bordet
Anderlecht, Belgium
Brussels - UNIV Saint-Luc
Brussels, Belgium
Start Date
July 8, 2015
Primary Completion Date
November 23, 2021
Completion Date
November 23, 2021
Last Updated
April 15, 2024
NCT03206060
NCT07542041
NCT06608446
NCT07541924
NCT04389632
NCT00033137
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions